Blog

New R&D Model Protects Performance in a Threatened Enrollment Landscape

DIA 2014 50^th Annual Meeting, SAN DIEGO, Calif. and BOSTON, Mass., June 16, 2014--BBK Worldwide, the leader in patient recruitment, today unveiled a new specialty in clinical trial marketing: adaptive  recruitment. Designed specifically to protect global enrollment integrity, within a changing or threatened landscape, adaptive recruitment helps sites and sponsors maximize tight budgets and timeframes by offering the tools and best-practices needed to ensure more informed recruitment and enrollment decisions – and the ability to seamlessly employ real-time corrections as needed. BBK Principal Matthew Stumm will discuss this new model in detail during his DIA Annual Meeting presentation, "Adopting New Strategies for the New Face of Patient Recruitment," on Tuesday, June 17 at 2:45 p.m. PST.

This is part one of a two-part series by Joan F. Bachenheimer, founding principal, and Matt Kibby, principal, technology and innovation, BBK Worldwide.

It’s a no brainer that applied metrics are invaluable for more accurately projecting patient recruitment; however, many people assume that once a trial is underway, it’s no longer necessary to measure anything until all the study data are accumulated. That’s just not true. There is tremendous value  in the ongoing application of metrics, throughout the entire study cycle, so much so that we sometimes find it hard to imagine how anyone can conduct a successful study without metrics. But we’re not talking about numbers for numbers’ sake. It takes a great deal of expertise to know which measurements to take and how to interpret the findings.

Editor’s note: This blog is the fourth in a seven-part series on TrialCentralNet^SM (TCN), a single infrastructure for managing everything from enrollment metrics to clinical trial reference documents through all phases of development and approval, as well as customized reports, training, and communications. The goal of this series is to give you the “backstory” – a BBK insider’s view of the system from the perspectives of those who build, manage, and rely on it. They’re passionate about the system they so tirelessly build and manage – and you’ll hear that come through in their writing.

Note: This blog contains excerpts from Justin’s recent article on operationalizing and distributing new patient recruitment programs, published in the March 2013 edition of European Pharmaceutical Contractor.

Mary D’Rozario first caught my attention through Twitter during the 2012 DIA Annual Meeting. Her Tweets about clinical research stood out from the crowd. Always insightful and witty, her messages offer a refreshing perspective from the industry. Interested in hearing more than just a 140 character Tweet, I asked her to talk about the importance of physicians and sites in clinical research.

I work on a lot of multi-protocol, multi-country, multi-language campaigns. Over the last four years or so, I’ve uncovered the top five MUST-HAVES for running said campaign. In order of importance…

If there was ever a clinical R&D version of the TV show, Jeopardy!  I think that one of the categories might go something like this:

We are excited to announce that BioPharm Clinical and BBK Worldwide will host a free, educational webinar to discuss new sources of patient pool demographic data and how they improve study feasibility and investigator selection. Featuring expert speaker Bonnie A. Brescia, founding principal at BBK Worldwide, the live online session will be held on November 15, 2012 at 12pm ET. RSVP to participate.

Just got out of a five-hour meeting. I was very impressed with this clinical team's desire to create a pilot for data sharing that is truly industry trendsetting. To run a clinical trial means to gather data — infinite amounts of data. I’m talking about multiple systems to house the data with each system having its own login and numerous input points.